Sangamo Therapeutics Inc
SGMO0.461USD
-0.090-16.29%
收盘 11/06, 16:00（美东）报价延迟15分钟
125.63M总市值
亏损市盈率 TTM
关于 Sangamo Therapeutics Inc 公司
Sangamo Therapeutics, Inc. 是一家基因药物公司，正在开发用于治疗神经系统疾病的药物。该公司的神经病学临床前开发专注于两个领域：开发表观遗传调控疗法以治疗严重的神经系统疾病，以及开发新型工程腺相关病毒 (AAV) 衣壳以将其疗法递送至预期的神经系统目标。该公司的锌指表观遗传调节剂非常适合潜在地治疗神经系统疾病，其衣壳发现平台正在将递送范围扩展到鞘内递送衣壳之外，包括中枢神经系统。其临床阶段候选产品是 Isaralgagene civaparvovec（也称为 ST-920），这是其全资拥有的用于治疗法布里病的基因治疗候选产品，以及其全资拥有的用于预防 HLA-A2 不匹配肾移植中免疫介导排斥的 CAR-Treg 细胞治疗候选产品 TX200。
Sangamo Therapeutics Inc简介
公司代码SGMO
公司名称Sangamo Therapeutics Inc
上市日期Apr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
员工数量183
证券类型Ordinary Share
年结日Apr 06
公司地址501 Canal Blvd.
城市RICHMOND
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94084
电话15109706000
网址https://www.sangamo.com/
公司代码SGMO
上市日期Apr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
Sangamo Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
304.91K
-12.64%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
198.35K
-3.27%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ms. Louise Wilkie
Ms. Louise Wilkie
Investor Relations
Investor Relations
--
--
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Robert F. Carey
Mr. Robert F. Carey
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
304.91K
-12.64%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
198.35K
-3.27%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2024
FY2023
暂无数据
地区USD
名称
营收
占比
United States
57.80M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
3.11%
Wasatch Global Investors Inc
2.68%
Renaissance Technologies LLC
2.27%
BlackRock Institutional Trust Company, N.A.
1.38%
Biogen Inc
1.08%
其他
89.48%
持股股东
持股股东
占比
The Vanguard Group, Inc.
3.11%
Wasatch Global Investors Inc
2.68%
Renaissance Technologies LLC
2.27%
BlackRock Institutional Trust Company, N.A.
1.38%
Biogen Inc
1.08%
其他
89.48%
股东类型
持股股东
占比
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
4.73%
Hedge Fund
4.45%
Corporation
1.08%
Individual Investor
1.07%
Research Firm
0.37%
Pension Fund
0.04%
Venture Capital
0.03%
Bank and Trust
0.02%
其他
80.70%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
319
51.76M
17.16%
-41.93M
2025Q2
349
61.18M
25.54%
-60.51M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
2023Q3
436
126.62M
71.56%
-23.29M
2023Q2
448
137.28M
80.06%
-15.05M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
9.37M
3.11%
--
--
Jun 30, 2025
Wasatch Global Investors Inc
8.08M
2.68%
+1.22M
+17.70%
Jun 30, 2025
Renaissance Technologies LLC
6.84M
2.27%
+3.67M
+115.88%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.18M
1.38%
-371.02K
-8.16%
Jun 30, 2025
Biogen Inc
3.25M
1.08%
-11.40M
-77.82%
Aug 14, 2024
Geode Capital Management, L.L.C.
2.33M
0.77%
+48.83K
+2.14%
Jun 30, 2025
GSA Capital Partners LLP
2.25M
0.74%
+1.28M
+132.40%
Jun 30, 2025
Two Sigma Investments, LP
2.08M
0.69%
+397.81K
+23.60%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.28M
0.42%
+183.97K
+16.76%
Jun 30, 2025
Ikarian Capital LLC
1.26M
0.42%
-600.00K
-32.25%
Jun 30, 2025
查看更多
持股ETF
更新时间: 17 小时前
更新时间: 17 小时前
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.63%
iShares Neuroscience and Healthcare ETF
0.34%
Global X Genomics & Biotechnology ETF
0.24%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
SPDR S&P Biotech ETF
0%
Global X Russell 2000 Covered Call ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.63%
iShares Neuroscience and Healthcare ETF
占比0.34%
Global X Genomics & Biotechnology ETF
占比0.24%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
iShares Micro-Cap ETF
占比0%
ProShares Hedge Replication ETF
占比0%
SPDR S&P Kensho New Economies Composite ETF
占比0%
SPDR S&P Biotech ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
